Navigation Links
Cepheid Welcomes Senior Vice President of Human Resources
Date:1/17/2012

SUNNYVALE, Calif., Jan. 17, 2012 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Mike Fitzgerald to the position of Senior Vice President, Human Resources, effective January 14, 2012. 

Mr. Fitzgerald joins Cepheid from Verigy, Inc., a wholly owned subsidiary of Advantest Corp., where he most recently served as Senior Vice President of Human Resources.  Prior to Verigy, Mr. Fitzgerald was Vice President of Human Resources at Varian, Inc. where he was responsible for the development and implementation of a global human resources program in support of the company's corporate goals for approximately 3,500 employees worldwide.  In total, Mr. Fitzgerald brings more than two decades of broad human resources experience to Cepheid, including Vodafone, PLC, and Xerox Financial Services.

In connection with his employment, the Compensation Committee of Cepheid's Board of Directors has granted Mr. Fitzgerald an option to purchase 56,000 shares of Cepheid common stock at the closing price of Cepheid common stock on Mr. Fitzgerald's employment commencement date and restricted stock units in respect of 10,000 shares of Cepheid common stock.  The option will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of grant and ratably monthly thereafter, and will expire after seven years from the grant date, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The restricted stock units will become exercisable by Mr. Fitzgerald over four years, with 25% vesting on the one-year anniversary of the grant and as to an additional 1/16th of the restricted stock units at the end of each three-month period thereafter, so long as Mr. Fitzgerald continues to be employed or provide services to Cepheid.  The option and restricted stock units were granted as inducement grants pursuant to Section 5635(c)(4) of The NASDAQ Stock Market Rules.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

CONTACTS:For Media Inquiries:For Investor Inquiries:Jared Tipton

Jacquie RossCepheid Corporate Communications

Cepheid Investor RelationsTel: (408) 400 8377

Tel: (408) 400 8329cepheid.com%7Cinvestor.relations@cepheid.com" target="_blank">jared.tipton@cepheid.com

investor.relations@cepheid.com


'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Receives FDA Clearance for Xpert Flu, Delivering Simultaneous Detection and Differentiation of Flu A, Flu B, and 2009 H1N1 Strain
2. Cepheid Schedules 2010 Third Quarter Financial Results Announcement and Webcast
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Expands Leadership Team With Appointment of Executive Vice President of Worldwide Commercial Operations
5. Cepheid Schedules 2009 Third Quarter Financial Results Announcement and Webcast
6. Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast
7. Cepheid Announces Symposium Speakers and Program Highlights for 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
8. Cepheid Reports 2009 First Quarter Results
9. Cepheid Schedules Fiscal 2009 First Quarter Financial Results Announcement and Webcast
10. Cepheid Announces New Diagnostic Technology to Aid World Efforts in Halting the Spread of Mycobacterium Tuberculosis (TB)
11. Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... UAS ... the launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, ... proud to add Target to its list of well-respected retailers. This list includes ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... SANTA MONICA, Calif. , June 23, 2016  The Prostate Cancer ... to pioneer increasingly precise treatments and faster cures for prostate cancer. Members of ... 77 institutions across 15 countries. Read More About the ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
Breaking Biology Technology:
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, Biometrics & ... & Other Service  The latest report from ... of the global Border Security market . Visiongain ... billion in 2016. Now: In November 2015 ... and hardware technologies for advanced video surveillance. ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
Breaking Biology News(10 mins):